JP7109547B2 - 真核ゲノム修飾のための操作されたＣａｓ９システム - Google Patents

真核ゲノム修飾のための操作されたＣａｓ９システム Download PDF

Info

Publication number
JP7109547B2
JP7109547B2 JP2020531575A JP2020531575A JP7109547B2 JP 7109547 B2 JP7109547 B2 JP 7109547B2 JP 2020531575 A JP2020531575 A JP 2020531575A JP 2020531575 A JP2020531575 A JP 2020531575A JP 7109547 B2 JP7109547 B2 JP 7109547B2
Authority
JP
Japan
Prior art keywords
sequence
engineered
protein
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505180A (ja
Inventor
ティモシー・シーベック
フーチアン・チェン
グレゴリー・デイビス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Publication of JP2021505180A publication Critical patent/JP2021505180A/ja
Priority to JP2022083820A priority Critical patent/JP7559005B2/ja
Application granted granted Critical
Publication of JP7109547B2 publication Critical patent/JP7109547B2/ja
Priority to JP2024114477A priority patent/JP2024161376A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2020531575A 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたＣａｓ９システム Active JP7109547B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022083820A JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたＣａｓ９システム
JP2024114477A JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたＣａｓ９システム

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631,304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720,525 2018-08-26
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022083820A Division JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたＣａｓ９システム

Publications (2)

Publication Number Publication Date
JP2021505180A JP2021505180A (ja) 2021-02-18
JP7109547B2 true JP7109547B2 (ja) 2022-07-29

Family

ID=65995829

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたＣａｓ９システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたＣａｓ９システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたＣａｓ９システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたＣａｓ９システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたＣａｓ９システム

Country Status (11)

Country Link
US (2) US10767193B2 (enExample)
EP (1) EP3752607A1 (enExample)
JP (3) JP7109547B2 (enExample)
KR (3) KR102684890B1 (enExample)
CN (1) CN111902536B (enExample)
AU (3) AU2019222568B2 (enExample)
BR (1) BR112020010479A2 (enExample)
CA (1) CA3084020C (enExample)
IL (2) IL274528B2 (enExample)
SG (1) SG11202007382TA (enExample)
WO (1) WO2019161290A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
EP3924475A1 (en) 2019-02-15 2021-12-22 Sigma-Aldrich Co. LLC Crispr/cas fusion proteins and systems
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
CA3156789A1 (en) 2019-12-17 2021-06-24 Erik Eastlund Genome editing in bacteroides
GB2594339B (en) * 2020-02-14 2023-02-08 Metagenomi Inc Enzymes with RUVC domains
AU2021236230B2 (en) * 2020-03-11 2024-09-26 Sigma-Aldrich Co. Llc High fidelity SpCas9 nucleases for genome modification
EP4632066A3 (en) * 2020-03-31 2025-12-24 Metagenomi, Inc. Class ii, type ii crispr systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
US20220145334A1 (en) * 2020-11-06 2022-05-12 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
MX2024002539A (es) 2021-08-27 2024-03-19 Metagenomi Inc Enzimas con dominios ruvc.
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
MY189533A (en) * 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013355214B2 (en) * 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
CA2894668A1 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
KR102733409B1 (ko) 2013-06-05 2024-11-21 듀크 유니버시티 Rna-가이드 유전자 편집 및 유전자 조절
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
CA2936646C (en) * 2014-01-24 2024-04-30 North Carolina State University Methods and compositions for sequences guiding cas9 targeting
WO2016033298A1 (en) * 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
KR102630014B1 (ko) * 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
DK3272867T3 (da) 2016-06-02 2019-12-02 Sigma Aldrich Co Llc Anvendelse af programmerbare dna-bindingsproteiner til forbedring af målrettet genommodifikation
ES2915562T3 (es) 2016-06-24 2022-06-23 Univ Colorado Regents Métodos para generar bibliotecas combinatorias con código de barras
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
AU2016432443B2 (en) * 2016-12-14 2024-04-18 Stichting Voor De Technische Wetenschappen Thermostable Cas9 nucleases
AU2018299995B2 (en) * 2017-07-11 2021-10-28 Sigma-Aldrich Co. Llc Using nucleosome interacting protein domains to enhance targeted genome modification
KR20250096876A (ko) * 2017-07-31 2025-06-27 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bosma, E. F. et al.，"Complete genome sequence of thermophilic Bacillus smithii type strain DSM 4216(T)"，Stand. Genomic. Sci.，2016年，Vol. 11; 52，pp. 1-11

Also Published As

Publication number Publication date
AU2019222568B2 (en) 2021-10-14
IL274528B2 (en) 2025-10-01
WO2019161290A1 (en) 2019-08-22
US10767193B2 (en) 2020-09-08
JP2021505180A (ja) 2021-02-18
BR112020010479A2 (pt) 2020-11-24
US20190249200A1 (en) 2019-08-15
AU2024202158A1 (en) 2024-05-02
CA3084020C (en) 2025-11-25
JP2024161376A (ja) 2024-11-19
CA3084020A1 (en) 2019-08-22
IL321024A (en) 2025-07-01
KR102465067B1 (ko) 2022-11-10
EP3752607A1 (en) 2020-12-23
IL274528A (en) 2020-06-30
CN111902536B (zh) 2024-07-30
IL274528B1 (en) 2025-06-01
KR102684890B1 (ko) 2024-07-12
AU2022200130B2 (en) 2024-03-07
AU2019222568A1 (en) 2020-05-21
JP2022122910A (ja) 2022-08-23
KR102494449B1 (ko) 2023-01-31
US12297449B2 (en) 2025-05-13
US20200354752A1 (en) 2020-11-12
JP7559005B2 (ja) 2024-10-01
KR20230022258A (ko) 2023-02-14
AU2022200130A1 (en) 2022-02-10
KR20200121342A (ko) 2020-10-23
SG11202007382TA (en) 2020-08-28
KR20220015502A (ko) 2022-02-08
CN111902536A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
JP7469285B2 (ja) 標的化されたゲノム修飾を増強するためのヌクレオソーム相互作用タンパク質ドメインの使用
JP2020530992A (ja) Ｃｒｉｓｐｒ／ｃａｓアクチベーターシステムのための合成ガイドｒｎａ
US20230287377A1 (en) Crispr/cas fusion proteins and systems
JP7629673B2 (ja) ゲノム改変のための高忠実度ＳｐＣａｓ９ヌクレアーゼ
BR122025004697B1 (pt) Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão
BR122025004697A2 (pt) Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos
HK40040051B (zh) 用於真核基因组修饰的改造的cas9系统
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification
HK40020657A (en) Using nucleosome interacting protein domains to enhance targeted genome modification

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220530

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220719

R150 Certificate of patent or registration of utility model

Ref document number: 7109547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250